1
Participants
Start Date
February 6, 2015
Primary Completion Date
May 17, 2017
Study Completion Date
October 31, 2017
EV/DNG (Qlaira, BAY86-5027)
Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
Multiple Locations
Lead Sponsor
Bayer
INDUSTRY